Raul Alvarez - Eli Lilly Independent Director

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;padding-top: 25px;;'>EL</div>
LLY -- USA Stock  

Report: 30th of July 2020  

  Director
Mr. Ralph Alvarez is Independent Director of Eli Lilly Co. Mr. Alvarez is executive chairman of Skylark Co., Ltd., a restaurant operator in Japan, a position he has held since January 2013. Previously, Mr. Alvarez served as president and chief operating officer of McDonald Corporationrationration from August 2006 until his retirement in December 2009. He also served as president of McDonald North America, with responsibility for all the McDonald restaurants in the U.S. and Canada. Prior to that, he was president of McDonald USA. Mr. Alvarez joined McDonald in 1994 and held a variety of leadership roles throughout his career, including chief operations officer and president of the central division, both with McDonald USA and president of McDonald Mexico. Prior to joining McDonald, he held leadership positions at Burger King Corporationrationration and Wendy International, Inc. Mr. Alvarez serves on the board of directors of Skylark Co., Ltd., Lowe Companies, Inc., and Dunkin Brands Group, Inc. Mr. Alvarez also serves on the President Council, the School of Business Administration Board of Overseers, and the International Advisory Board of the University of Miami. He was previously a member of the boards of McDonald Corporationrationration and KeyCorporationration
Age: 63  Director Since 2009      
317 276-2000  www.lilly.com

Eli Lilly Management Efficiency

Eli Lilly And has Return on Asset of 10.25 % which means that on every $100 spent on asset, it made $10.25 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 192.05 %, implying that it generated $192.05 on every 100 dollars invested. Eli Lilly management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Eli Lilly Return on Average Assets are fairly stable at the moment as compared to the past year. Eli Lilly reported Return on Average Assets of 0.22 in 2019. Return on Average Equity is likely to grow to 3.19 in 2020, whereas Return on Investment is likely to drop 25.98 in 2020. Eli Lilly Total Assets are fairly stable at the moment as compared to the past year. Eli Lilly reported Total Assets of 39.29 Billion in 2019. Current Assets is likely to grow to about 15.7 B in 2020, whereas Goodwill and Intangible Assets are likely to drop slightly above 8.9 B in 2020. Eli Lilly Current Liabilities is fairly stable at the moment as compared to the past year. Eli Lilly reported Current Liabilities of 11.78 Billion in 2019. Tax Liabilities is likely to grow to about 6.4 B in 2020, whereas Total Liabilities is likely to drop slightly above 33.1 B in 2020.
The company has 17.63 B in debt with debt to equity (D/E) ratio of 5.52, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Eli Lilly And has a current ratio of 1.09, demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Kelly KramerGilead Sciences
2016
Tomas GelabertGrifols S A
2016
Christine SeidmanMerck Company
2020
Per WoldOlsenGilead Sciences
2010
Manvinder BangaGlaxoSmithKline PLC
2016
Pierre LandoltNovartis AG
1996
Philip BroadleyAstrazeneca PLC
2017
Marillyn HewsonJohnson Johnson
2019
Robert KidderMerck Company
2005
Genevieve BergerAstrazeneca PLC
2012
Simon DingemansGlaxoSmithKline PLC
2011
Laurie GlimcherBristol Myers Squibb
N/A
Dinesh PaliwalBristol Myers Squibb
2013
Alan LacyBristol Myers Squibb
2008
Rochelle LazarusMerck Company
2004
Thomas GlanzmannGrifols S A
2017
Marcus WallenbergAstrazeneca PLC
1999
Mark WeinbergerJohnson Johnson
2019
Alicia SecorGW Pharmaceuticals Plc
2017
Vindi BangaGlaxoSmithKline PLC
2017
Nancy AndrewsNovartis AG
2015

Company Summary

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 33815 people.Eli Lilly And (LLY) is traded on BATS Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN 46285, United States and employs 33,815 people. Eli Lilly And was previously known as ELI LILLY Co and was traded on BATS Exchange under the symbol LLY. Eli Lilly is listed under Pharmaceutical Products category by Fama And French industry classification.

Eli Lilly And Leadership Team

Ellen Marram, Lead Independent Director
Kathi Seifert, Independent Director
Ralph Alvarez, Independent Director
Jamere Jackson, Independent Director
Joshua Smiley, Chief Financial Officer, Senior Vice President
Anat Hakim, Senior Vice President General Counsel
Fionnuala Walsh, Senior Vice President - Global Quality
Johna Norton, Senior Vice President - Global Quality
Juan Luciano, Lead Independent Director
J Fyrwald, Independent Director
Alfonso Zulueta, Senior Vice President and President - Emerging Markets business
Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health
John Lechleiter, Chairman, CEO and Pres
Anne White, Senior Vice President and Presidentident - Lilly Oncology
Karen Horn, Independent Director
Leigh Pusey, Senior Vice President - Corporate Affairs and Communications
Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Darren Carroll, Senior Vice President - Corporate Business Development
Patrik Jonsson, Senior Vice President and President - Lilly Bio-Medicines
William Kaelin, Independent Director
Karen Walker, Independent Director
Christi Shaw, Senior Vice President and President - Lilly Bio-Medicines
Barton Peterson, Senior Vice President - Corporate Affairs and Communications
Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee
Enrique Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
Raul Alvarez, Independent Director
Marschall Runge, Independent Director
Michael Harrington, Executive Vice President, General Counsel
David Hoover, Independent Director
Maria Crowe, President - Manufacturing Operations
Myles ONeill, Senior Vice President and President - Manufacturing Operations
David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines
Daniel Skovronsky, Senior Vice President - Science and Technology, and President Lilly Research Laboratories
Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research Laboratories
Carolyn Bertozzi, Independent Director
Erik Fyrwald, Independent Director
Aarti Shah, Senior Vice President - Chief Information and Digital Officer
Susan Mahony, Senior Vice President and President - Lilly Oncology
Jackson Tai, Independent Director
Michael Eskew, Independent Director
Katherine Baicker, Independent Director
Stephen Fry, Senior Vice President - Human Resources and Diversity
Michael Mason, Senior Vice President and President Lilly Diabetes
Franklyn Prendergast, Independent Director

Stock Performance Indicators

Current Sentiment - LLY

Eli Lilly And Investor Sentiment

Predominant part of Macroaxis users are now bullish on Eli Lilly And. What is your opinion about investing in Eli Lilly And? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page